Advertisement


Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

2015 NCCN Annual Conference

Advertisement

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surrounded the first meeting, oncologists’ embrace of the guidelines, and how the organization has evolved over the past 20 years.



Related Videos

Breast Cancer

Ingrid A. Mayer, MD, on New Therapies for Hormone-Sensitive Advanced Breast Cancer

Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.

Lung Cancer

John C. Grecula, MD, on the Role of Radiation Therapy in Management of SCLC

John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation for patients with small cell lung cancer and advances that include prophylactic cranial radiotherapy, thoracic radiotherapy, and the use of PET-CT.

Bladder Cancer

Peter E. Clark, MD, on a Guideline Update in the Management of Bladder Cancer

Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.

Pancreatic Cancer
Hematologic Malignancies

Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.

Leukemia

Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months will ultimately prove useful.

Advertisement

Advertisement




Advertisement